SequelSEC

Neuraxis, INC NRXS

Electromedical & Electrotherapeutic Apparatus · CIK 0001933567 · Fiscal year ends 1231

Revenue
$5.32M
Fiscal year ended 2026-06-30
Operating income
-$7.68M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Neuraxis, INC (NRXS) reported revenue of $5.32M and net income of -$7.68M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Neuraxis, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Neuraxis, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$5.32M
Cost of revenue$768.08K
Gross profit$4.55M
Operating income-$7.68M
Net income-$7.68M
Research & development$650.94K
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$8.55M
Selling & marketingUnavailable

Balance

Neuraxis, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$8.32M
Total assets$10.00M
Current assets$9.41M
Total liabilities$3.26M
Current liabilities$3.10M
Total equity incl. NCI$6.74M
Temporary (mezzanine) equityUnavailable
Inventory$277.31K
Accounts receivable$432.92K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$791.59K

Cash flow

Neuraxis, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$5.62M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$8.07M
Net change in cash$2.33M
Stock-based compensation$1.29M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$73.23K

Derived

Neuraxis, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin85.6%
Operating margin-144.5%
FCF marginUnavailable
SBC / revenue24.2%
Current ratio3.04x
Revenue YoY growth65.2%
Net margin-144.4%
R&D / revenue12.2%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NRXS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.